Deciphera Pharmaceuticals Inc (OQ:DCPH)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 200 Smith St
WALTHAM MA 02451-0099
Tel: 1-212-6001902
Website: https://www.deciphera.com
IR: See website
<
Key People
Steven L. Hoerter
President, Chief Executive Officer, Director
Thomas J. Kelly
Chief Financial Officer, Executive Vice President, Treasurer
Dashyant Dhanak
Executive Vice President, Chief Scientific Officer
Matthew L. Sherman
Executive Vice President, Chief Medical Officer
Kelley Dealhoy
Senior Vice President, Chief Business Officer
Daniel C. Martin
Senior Vice President, Chief Commercial Officer
Jama Pitman
Senior Vice President, Regulatory, Quality, Portfolio Management
   
Business Overview
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
Financial Overview
For the fiscal year ended 31 December 2023, Deciphera Pharmaceuticals Inc revenues increased 22% to $163.4M. Net loss increased 9% to $194.9M. Revenues reflect U.S. segment increase of 25% to $121.5M, Rest of world segment increase of 40% to $19.6M, Germany segment increase of 25% to $18M. Higher net loss reflects pharmaceutical, biotechnology segment loss increase of 15% to $211M.
Employees: 355 as of Jan 31, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $839.53M as of Dec 31, 2023
Annual revenue (TTM): $163.36M as of Dec 31, 2023
EBITDA (TTM): -$208.86M as of Dec 31, 2023
Net annual income (TTM): -$194.94M as of Dec 31, 2023
Free cash flow (TTM): -$147.48M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 80,800,062 as of Jan 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.